WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555510
CAS#: 2216753-86-3 (HCl)
Description: LYN-1604 is a novel activator of ULK1, inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. LYN-1604 could induce cell death, associated with autophagy by the ULK complex (ULK1-mATG13-FIP200-ATG101) in MDA-MB-231 cells. To further explore LYN-1604-induced autophagic mechanisms, we found some potential ULK1 interactors, such as ATF3, RAD21, and caspase3, by performing comparative microarray analysis. LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.
MedKoo Cat#: 555510
Name: LYN-1604 HCl
CAS#: 2216753-86-3 (HCl)
Chemical Formula: C33H44Cl3N3O2
Exact Mass:
Molecular Weight: 621.084
Elemental Analysis: C, 63.82; H, 7.14; Cl, 17.12; N, 6.77; O, 5.15
Related CAS #: 2088939-99-3 (free base) 2216753-86-3 (HCl) 2310109-38-5 (2HCl)
Synonym: LYN-1604 HCl; LYN-1604 hydrochloride; LYN-1604; LYN 1604; LYN1604;
IUPAC/Chemical Name: 2-[bis(2-methylpropyl)amino]-1-[4-[2-(2,4-dichlorophenyl)-2-(2-naphthalenylmethoxy)ethyl]-1-piperazinyl]-ethanone hydrochloride
InChi Key: KWFDUNOLEJSFBQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C33H43Cl2N3O2.ClH/c1-24(2)19-37(20-25(3)4)22-33(39)38-15-13-36(14-16-38)21-32(30-12-11-29(34)18-31(30)35)40-23-26-9-10-27-7-5-6-8-28(27)17-26;/h5-12,17-18,24-25,32H,13-16,19-23H2,1-4H3;1H
SMILES Code: ClC1=CC=C(C(OCC2=CC=C3C=CC=CC3=C2)CN4CCN(C(CN(CC(C)C)CC(C)C)=O)CC4)C(Cl)=C1.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC). |
| In vitro activity: | This study finds that ASD patient-derived neurons with a functional loss of TSC2, in addition to possessing neuronal hyperactivity, develop a dysfunctional neuronal network with reduced synchronisation of neuronal bursting and lower spatial connectivity. The mTOR inhibitor rapamycin suppresses neuronal hyperactivity, but does not increase synchronised network activity, whereas activation of AMPK restores some aspects of network activity. In contrast, the ULK1 activator, LYN-1604, increases the network behaviour, shortens the network burst lengths and reduces the number of uncorrelated spikes. Reference: Mol Autism. 2020 Oct 19;11(1):80. https://pubmed.ncbi.nlm.nih.gov/33076974/ |
| In vivo activity: | It is unclear whether corneal autophagy participates in ocular surface inflammation observed in DED. To test this involvement, dry eye (DE) was induced in female C57BL/6 mice housed in a controlled environment by subcutaneous injection of scopolamine. Treatment with LYN-1604, an activator of autophagy, alleviated the clinical indications in DE mice, including tear production and corneal fluorescence staining. LYN-1604 also reduced the corneal levels of inflammatory response products, including tumor necrosis factor alpha (TNF-α) and matrix metalloproteinases-3 and -9. Reference: Exp Eye Res. 2019 Jul;184:126-134. https://pubmed.ncbi.nlm.nih.gov/31018117/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 100.0 | 161.01 |
The following data is based on the product molecular weight 621.084 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Alsaqati M, Heine VM, Harwood AJ. Pharmacological intervention to restore connectivity deficits of neuronal networks derived from ASD patient iPSC with a TSC2 mutation. Mol Autism. 2020 Oct 19;11(1):80. doi: 10.1186/s13229-020-00391-w. PMID: 33076974; PMCID: PMC7574213. 2. Ouyang L, Zhang L, Fu L, Liu B. A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer. Autophagy. 2017 Apr 3;13(4):777-778. doi: 10.1080/15548627.2017.1283470. Epub 2017 Feb 6. PMID: 28165887; PMCID: PMC5388211. 3. Ma S, Yu Z, Feng S, Chen H, Chen H, Lu X. Corneal autophagy and ocular surface inflammation: A new perspective in dry eye. Exp Eye Res. 2019 Jul;184:126-134. doi: 10.1016/j.exer.2019.04.023. Epub 2019 Apr 21. PMID: 31018117. 4. Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, He G, Yang S, Ouyang L, Liu B. Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. Chem Sci. 2017 Apr 1;8(4):2687-2701. doi: 10.1039/c6sc05368h. Epub 2017 Jan 9. PMID: 28553505; PMCID: PMC5433508. |
| In vitro protocol: | 1. Alsaqati M, Heine VM, Harwood AJ. Pharmacological intervention to restore connectivity deficits of neuronal networks derived from ASD patient iPSC with a TSC2 mutation. Mol Autism. 2020 Oct 19;11(1):80. doi: 10.1186/s13229-020-00391-w. PMID: 33076974; PMCID: PMC7574213. 2. Ouyang L, Zhang L, Fu L, Liu B. A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer. Autophagy. 2017 Apr 3;13(4):777-778. doi: 10.1080/15548627.2017.1283470. Epub 2017 Feb 6. PMID: 28165887; PMCID: PMC5388211. |
| In vivo protocol: | 1. Ma S, Yu Z, Feng S, Chen H, Chen H, Lu X. Corneal autophagy and ocular surface inflammation: A new perspective in dry eye. Exp Eye Res. 2019 Jul;184:126-134. doi: 10.1016/j.exer.2019.04.023. Epub 2019 Apr 21. PMID: 31018117. 2. Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, He G, Yang S, Ouyang L, Liu B. Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. Chem Sci. 2017 Apr 1;8(4):2687-2701. doi: 10.1039/c6sc05368h. Epub 2017 Jan 9. PMID: 28553505; PMCID: PMC5433508. |
1: Ma S, Yu Z, Feng S, Chen H, Chen H, Lu X. Corneal autophagy and ocular surface
inflammation: A new perspective in dry eye. Exp Eye Res. 2019 Apr 21;184:126-134.
doi: 10.1016/j.exer.2019.04.023. [Epub ahead of print] PubMed PMID: 31018117.
2: Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, He G, Yang S, Ouyang L, Liu
B. Discovery of a small molecule targeting ULK1-modulated cell death of triple
negative breast cancer in vitro and in vivo. Chem Sci. 2017 Apr 1;8(4):2687-2701.
doi: 10.1039/c6sc05368h. Epub 2017 Jan 9. PubMed PMID: 28553505; PubMed Central
PMCID: PMC5433508.
3: Ouyang L, Zhang L, Fu L, Liu B. A small-molecule activator induces
ULK1-modulating autophagy-associated cell death in triple negative breast cancer.
Autophagy. 2017 Apr 3;13(4):777-778. doi: 10.1080/15548627.2017.1283470. Epub
2017 Feb 6. PubMed PMID: 28165887; PubMed Central PMCID: PMC5388211.
